4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Abbisko Cayman Limited (2256) operates in the Biotechnology industry and is headquartered in Shanghai, China with about 276 employees. Its market capitalization is roughly CNY 8 billion. In the fiscal year ended 2025-12-31, 2256 reported CNY 612M in revenue and CNY 55M in net income.
Abbisko Cayman Limited, together with its subsidiaries, engages in the research, discovery, and development of pharmaceutical products in Mainland China and the European Union.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CNY 612M | CNY 504M | CNY 19M | CNY 0M | — |
| Gross Profit | CNY 612M | CNY 504M | CNY 19M | CNY 0M | — |
| Operating Income (EBIT) | CNY 43M | (CNY 8M) | (CNY 490M) | (CNY 487M) | — |
| Net Income | CNY 55M | CNY 28M | (CNY 432M) | (CNY 496M) | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 2.4B | CNY 2.1B | CNY 2.1B | CNY 2.5B | — |
| Total Liabilities | CNY 430M | CNY 149M | CNY 134M | CNY 143M | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2256 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms